Brief: Appili Therapeutics Announces Issuance Of Patent For Ati-1501 Liquid Oral Reformulation Of Metronidazole
24/05/2023 12:20
May 24 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS ANNOUNCES ISSUANCE OF PATENT FOR
ATI-1501
LIQUID ORAL REFORMULATION OF METRONIDAZOLE
* APPILI THERAPEUTICS INC - FDA ESTABLISHED ATI-1501 A
PRESCRIPTION DRUG USER FEE ACTION DATE OF SEPTEMBER 23, 2023
Source text for Eikon: ID:nBw7dFZTva
Further company coverage: APLI.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez